Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06671496 · ClinicalTrials.gov registry record · Phase 3

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines

A Phase 3 study of Psoriatic Arthritis, sponsored by Takeda.

Recruiting
Registry status
Phase 3
Development phase
600
Enrollment target
20
Study locations

NCT06671496 is a Phase 3 study of Psoriatic Arthritis that is actively recruiting participants, run by Takeda. The registered enrollment target is 600 participants, below the 840-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (29% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06671496, a Phase 3 study of Psoriatic Arthritis, is actively recruiting participants, sponsored by Takeda.

RECRUITING
Registry status
Phase 3
Development phase
600 participants
Enrollment target
20
Study locations

Study Summary

Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA based on their previous experience with specific treatments. The participants will be treated with either zasocitinib, or placebo. Participants will be in the study for up to 60 weeks.

Conditions Studied

Psoriatic Arthritis

Interventions

  • DRUG Placebo
  • DRUG Zasocitinib

Study Locations (20)

Florida

  • RASF- Clinical Research Center - Boca Raton
  • Direct Helpers Medical Center - Hialeah
  • IRIS Research and Development | Plantation, FL - Plantation
  • BayCare Medical Group - St. Petersburg

Arizona

  • Arizona Arthritis & Rheumatology Research, PLLC | Phoenix, AZ - Mesa
  • Arizona Arthritis & Rheumatology Research, PLLC | Phoenix, AZ - Phoenix
  • Arizona Arthritis & Rheumatology Research, PLLC | Phoenix, AZ - Tucson

Texas

  • AARR- Lone Star Arthritis & Rheumatology Associates - Fort Worth
  • Biopharma Informatic | Hassan - Houston
  • Advanced Rheumatology of Houston - The Woodlands - The Woodlands

California

  • Biovin Enterprises LLC dba Medvin Clinical Research | Covina, CA - Covina

Georgia

  • North Georgia Rheumatology Group PC - Lawrenceville

Illinois

  • Clinic of Robert Hozman - Skokie

Kentucky

  • Graves Gilbert Clinic - Bowling Green

Maryland

  • Johns Hopkins Hospital - Baltimore

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2025-03-10
Est. Completion 2028-01-26
Phase Phase 3

Sponsor

Takeda

408 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06671496

The ClinicalTrials.gov registry entry for NCT06671496 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 840-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (29% lower). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Psoriatic Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06671496 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, Arizona, Texas.

Frequently Asked Questions

What is clinical trial NCT06671496 about?

NCT06671496 is a clinical study titled "A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines". Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA based on their previous experience with specific treatments. Th...

What is the current status of trial NCT06671496?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2025-03-10. Estimated completion is 2028-01-26.

What conditions does trial NCT06671496 study?

This clinical trial studies the following conditions: Psoriatic Arthritis.

What interventions are being tested in trial NCT06671496?

The interventions under investigation include: Placebo (DRUG), Zasocitinib (DRUG).

Who is sponsoring clinical trial NCT06671496?

This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06671496 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Psoriatic Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Psoriatic Arthritis

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.